Global bio-pharmaceutical company Takeda on Wednesday said it has initiated development of a plasma-derived therapy for new coronavirus (COVID-19) and produce the therapy termed as "TAK-888".
The company said in a statement that it would share with members of the US Congress the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19.
The would also study whether Takeda's currently marketed and pipeline products may be effective treatments for infected patients.
SARS-CoV-2 is the virus that causes COVID-19.
Hyper immune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19.
As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential therapy, referring to as "TAK-888," the company said.
"As a company dedicated to the health and well-being of people around the world, we will do all that we can to address the novel coronavirus threat," said Dr Rajeev Venkayya, President of Takeda's Vaccine Business Unit and co-lead of the company's COVID-19 response team.
"We have identified relevant assets and capabilities across the company and are hopeful that we can expand the treatment options for patients with COVID-19 and the providers caring for them," Venkayya added.
More than 92,000 cases have been confirmed worldwide and the number of deaths from the new virus has reached 3,110 globally, according to the WHO.
Takeda is currently in discussions with multiple national health and regulatory agencies and health care partners in the US, Asia and Europe to expeditiously move the research into "TAK-888" forward.
This requires access to source plasma from people who have successfully recovered from COVID-19 or who have been vaccinated, once a vaccine is developed.
These convalescent donors have developed antibodies to the virus that could potentially mitigate severity of illness in COVID-19 patients and possibly prevent it, said the company.
"Plasma-derived therapies are critical, life-saving medicines that thousands of people with rare and complex diseases rely on every day around the world," said Dr Chris Morabito, Takeda's Head of Research and Development, Plasma-Derived Therapies Business Unit.
In addition, Takeda is exploring whether select marketed therapies and molecules in its drug library could be viable candidates for the effective treatment of COVID-19.
Braving the scorching heat, Tripura East records over 80 pc turnout
Despite the scorching heat, over 80 per cent of the 14 lakh voters cast their votes in the Tripura East Lok Sabha constituency where polling was held under a heavy security cover on Friday.
NCPCR initiates action against Mehbooba Mufti for 'using school children for election campaign'
In a significant development, the National Commission for Protection of Child Rights (NCPCR) on Friday took cognisance of a report on 'X' accusing PDP President and Anantnag-Rajouri Lok Sabha seat candidate Mehbooba Mufti of using school children for campaigning in the election.
PM Modi takes opposition to cleaners on EVMs, once again
Calling it a "historic day", Prime Minister Narendra Modi on Friday lauded the Supreme Court's decision to dismiss a batch of petitions seeking mandatory cross-verification of the votes cast in Electronic Voting Machines (EVMs) with Voter-Verifiable Paper Audit Trail (VVPAT) slips.
LS Poll: Over 1000 villagers did not cast vote; shows protest against bad road condition, improper drinking water facility
Over 1000 villagers of Maldapara of Gandacherra subdivision in Dhalai Tripura district on Friday boycotted the second phase of polling to East Tripura constituency and refrained from casting their vote as part of their agitation against bad condition of road in their village.
PM Modi roasts Cong, says former PM's video on 'priority for Muslims' demolishes its canards
Prime Minister Narendra Modi on Friday stepped up his offensive on the Congress and said that his plainspeak on the party’s double standards has ruffled many feathers in the INDIA bloc, so much so, that they have launched a tirade at him for speaking the truth.
CBI recovers huge cache of arms, explosives from house of Shahjahan’s relative at Sandeshkhali
The CBI on Friday afternoon conducted a raid at the residence of a relative of suspended Trinamool Congress leader Sheikh Shahjahan at Sandeshkhali in North 24 Parganas District and seized a huge cache of firearms and explosives.
Tripura records 54.47% turnout recorded till 1 PM in 2nd phase polling to East
The second phase of polling for the East Tripura Parliamentary constituency is underway amid tight security coverage, while 54.47% voter turnout was recorded till 1 pm on Friday. Voting commenced at 7 am and will continue until 6 pm. Tripura recorded the highest turnout at 36.42 per cent till 11 am.
DMs, SPs of violence-hit MP districts transferred
The farmers agitation entered its eighth day on Thursday. The peasants have been on strike since June 1, demanding loan waiver and fair price for their produce.